PD-1 inhibitor exposure, hepatic metastasis and independent prognostic factors in recurrent or metastatic esophageal cancer: a single-center retrospective cohort study
Background PD-1 inhibitor-based chemoimmunotherapy is now standard first-line treatment for advanced esophageal cancer. Real-world data remain scarce, and which clinical variables still carry prognostic weight once immunotherapy is routine is not settled. Methods Consecutive patients with recurrent or initial metastatic esophageal cancer treated at our center, who had received at least one line of systemic therapy and had complete follow-up, were reviewed. Overall survival (OS) and progression-free survival (PFS) were both measured from the diagnosis of recurrent or metastatic disease, when first-line therapy began, and groups were compared by the log-rank test. Prognostic factors were examined by Cox regression stratified by disease setting, together with subgroup and sensitivity analyses. Results Seventy-eight patients were analyzed (median age 62 years; 82.1% male; 80.8% squamous; 46 initial metastatic). 53 of the 73 patients with known exposure (72.6%) had received a PD-1 inhibitor. Median follow-up was 39.4 months, median OS was 24.4 months (95% CI 17.7-32.6) and median PFS 9.3 months (95% CI 7.5-15.8). PD-1 exposure raised the objective response rate (43.4% vs 5.0%; P = 0.002) without improving OS (adjusted HR 1.39) or PFS (adjusted HR 0.78), and stricter definitions of exposure and landmark analyses left these estimates unchanged. Liver metastasis was the only variable associated with both endpoints after adjustment (OS HR 2.97, 95% CI 1.42-6.19; PFS HR 2.38, 95% CI 1.15-4.92), and the association was at least as strong among the 63 patients with squamous cell carcinoma (OS HR 4.18). PD-1 exposure was associated with longer PFS in an exploratory analysis of the 45 patients with initialmetastatic disease (adjusted HR 0.36, 95% CI 0.14-0.93). Conclusions Among the patients with advanced esophageal squamous cell carcinoma included in our study, the median OS was 24.4 months and the median PFS was 9.3 months. Both outcomes exceeded historical real-world data for this setting, supporting the feasibility of routine clinical use of first-line chemoimmunotherapy. PD-1 exposure improved the response rate but not survival, in an observational comparison the likeliest explanation is confounding by indication. Liver metastasis was the strongest independent adverse prognostic factor and indicates the group in greatest need of new treatment options.
Authors
- Yaqing Dai (ORCID: https://orcid.org/0009-0005-3170-112X)
- Jiancheng Li
- Zhou Rui
Institutions
- Fujian Medical University (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-21
- DOI
- https://doi.org/10.21203/rs.3.rs-11700860/v1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- preprint